What researchers published on Pompe-betegség
1192 papers, newest first.
Showing 200 of 1192
Patient perspectives of participation in clinical studies in late-onset Pompe disease: Structured exit interviews from cipaglucosidase alfa plus miglustat studies.Therapeutic advances in rare disease
High-Risk Screening for Late-Onset Pompe Disease in Northern China: Prevalence, Genotypic Spectrum, and Diagnostic Challenges.JIMD reports
High-Fat, High-Protein, Carbohydrate-Restricted Dietary Interventions in Pompe Disease: A Case Series with Long-Term Follow-Up.Annals of nutrition & metabolism
A novel technology-driven enzyme replacement therapy for Pompe disease.Molecular therapy. Advances
ÁttekintésInfusion-associated reactions during enzyme replacement therapy in late-onset Pompe disease: a systematic review and proposed management algorithm.Molecular genetics and metabolism
EsetismertetésRecurrent Reactions to Enzyme Replacement Therapy in Infantile-Onset Pompe Disease: A Case of Immunologic Barriers to Drug Tolerance.American journal of medical genetics. Part A
EsetismertetésEarly Cardiac Involvement in Late-Onset Pompe Disease: A Case Report from an Iranian Consanguineous Family.Iranian journal of child neurology
Szisztematikus áttekintésThe Genetic Landscape of Pompe Disease in the Middle East, North Africa, and Turkey (MENAT Region): A Systematic Review of GAA Variants and Genotype-Phenotype Correlation.International journal of molecular sciences
Home-Based Versus Hospital-Based Administration of Enzyme Replacement Therapy for Late-Onset Pompe Disease in Greece: A Cost-Utility and Budget Impact Analysis.Applied health economics and health policy
Efficacy and safety of cipaglucosidase alfa plus miglustat in Japanese adults with late-onset Pompe disease: a case series from clinical trials.BMJ neurology open
ÁttekintésInfantile-Onset Pompe Disease: Current Therapeutic Landscape, Clinical Challenges, and Future Horizons.Cureus
Of Pompe and Circumstance: A Case Review of Late Onset Pompe Disease in a 52-Year-Old Male.Case reports in rheumatology
Evaluation of Pompe Disease from a Broad and Systemic Perspective.Journal of clinical practice and research
Identifying regulatory muscle processes in infantile and adult Pompe patients using a multi-omic and morphological approach.Brain pathology (Zurich, Switzerland)
Generation and characterization of a human iPSC line (XACHi022-A) derived from an asymptomatic carrier of the GAA c.2051C > A (p.P684Q) variant.Stem cell research
Two novel GAA missense variants and a known VUS in pompe disease: Functional characterization and pharmacological chaperone therapy.Genes & diseases
A High-Fat, High-Protein, Carbohydrate-Restricted Dietary Interventions in Pompe Disease: A Case Series with Long-Term Follow-Up.Annals of nutrition & metabolism
Nocturnal sleep abnormalities occur before motor function deterioration in early-treated patients with infantile-onset Pompe disease: a two-decade newborn screening cohort study.Neuromuscular disorders : NMD
Enzyme replacement therapy (ERT) combined with transient low-dose methotrexate (TLD-MTX) results in age- and disease-dependent immune profile changes in Infantile- vs. late-onset Pompe disease patients.Frontiers in immunology
EsetismertetésLate-Onset Pompe Disease.The New England journal of medicine
Megfigyeléses vizsgálatScreening for potential late-onset Pompe disease patients among individuals with suspected sleep apnea: A prospective, multicenter observational Cohort Study in Japan (PSSAP-J Study).Sleep & breathing = Schlaf & Atmung
Corrigendum to "Early detection in action: developing and refining newborn screening for Pompe disease in North Carolina" [Mol. Genet. Med. 149 (1-2) (2026) 110252].Molecular genetics and metabolism
Preliminary clinical application of two-dimensional speckle tracking echocardiography in adult-onset glycogen storage disease type II.Archives of physiology and biochemistry
The Effect of Anti-drug Antibodies on the Bioavailability of Alglucosidase Alfa in Classic Infantile Pompe Disease.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ÁttekintésGenome Editing for Glycogen Storage Diseases.Journal of inherited metabolic disease
Epilepsy Is Part of the CNS Phenotype in Classic Infantile Pompe Disease.Neurology. Genetics
Early detection in action: developing and refining newborn screening for Pompe disease in North Carolina.Molecular genetics and metabolism
Functional characterization of 42 GAA missense variants using a validated in vitro cellular functional assay.Molecular genetics and metabolism
Nociceptive pain in late-onset Pompe disease: prevalence, distribution, and clinical correlates.Journal of neurology
GAA engineered to improve cellular uptake enhances correction in a preclinical hematopoietic stem cell gene therapy model of Pompe disease.Molecular therapy. Advances
A Protocol for Multidisciplinary Rehabilitation Combined with Enzyme Replacement Therapy for Ventilator Weaning in Late-Onset Pompe Disease.Journal of visualized experiments : JoVE
Pompe Disease: From a Cardiovascular Lens.Cardiology in review
Megfigyeléses vizsgálatExpiratory phase lung mechanics in late-onset Pompe disease: a multicenter study using oscillometry to identify specific breathing abnormalities.Orphanet journal of rare diseases
AAV9-mediated GAA gene therapy following enzyme replacement therapy discontinuation in children with infantile-onset Pompe disease.EClinicalMedicine
Disease duration and phenotypic heterogeneity in late-onset Pompe disease: Implications for individualized therapy.Molecular genetics and metabolism
ÁttekintésDefining the therapeutic corridor of stability in enzyme replacement therapy for Pompe disease: a position statement.Orphanet journal of rare diseases
Szisztematikus áttekintésCentral nervous system histopathological findings in classic infantile Pompe disease: a systematic review with clinical relevance.Journal of neurology
Home Infusion With Recombinant Human α-Glucosidase in Children With Pompe Disease: The Dutch Experience Over 20 Years Across the Spectrum From Classic Infantile to Late-Onset Phenotypes.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Real-Life Effectiveness After Switching to Avalglucosidase Alfa in Late-Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study.European journal of neurology
A disease progression model comparing the long-term mobility and respiratory outcomes of adults with late-onset Pompe disease receiving cipaglucosidase alfa plus miglustat versus alglucosidase alfa.Journal of comparative effectiveness research
ÁttekintésA Comprehensive Update on Pompe Disease: From Existing Therapies to Emerging Curative Strategies.International journal of molecular sciences
Neonatal gene therapy with AAV2/8-LSPhGAA improves hypertrophic cardiomyopathy in the Gaac.1826dupA knock-in murine model.Molecular genetics and metabolism
Evaluation of electrical impedance myography as a noninvasive musculoskeletal biomarker in infantile- and late-onset Pompe disease.Genetics in medicine : official journal of the American College of Medical Genetics
Impact of Enzyme Replacement Therapy on Patients with Late Onset Pompe Disease - Real World Data from a Developing Country.Indian journal of pediatrics
Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.Molecular therapy : the journal of the American Society of Gene Therapy
Bayesian multivariate linear mixed-effects models with varied association structures.Statistical methods in medical research
Managing Pompe Disease and Enzyme Replacement Therapy During Pregnancy: Challenges and Considerations.European journal of neurology
Accumulation of membrane repair-associated proteins and mature myostatin are novel markers of muscle pathophysiology in Pompe disease.Acta neuropathologica communications
Pediatric sleep-disordered breathing in Pompe disease in the era of enzyme replacement therapy: A retrospective cohort study.Molecular genetics and metabolism
High prevalence of GAA c.[752C > T;761C > T] haplotype complicates high-risk screening for Pompe disease in the Chinese population.Molecular genetics and metabolism
EsetismertetésRhizobium radiobacter bloodstream infection associated with long-term central venous access in an infant with Pompe disease.Le infezioni in medicina
TRPML1 agonists synergize with enzyme replacement therapy in fibroblasts from Pompe disease patients.Journal of translational medicine
EsetismertetésWhen 'Liver Enzymes' Are Not Hepatic: Late-Onset Pompe Disease.The Medical journal of Australia
Longitudinal Assessment of Muscle Involvement in Late-Onset Pompe Disease Using Quantitative MRI: A Prospective Cohort Study.Journal of cachexia, sarcopenia and muscle
Quantitative Muscle MRI of the Lower Extremities Reveals Different Patterns of Involvement in Classic Infantile and Young Late-Onset Pompe Patients.Journal of inherited metabolic disease
Unfavorable cardiovascular risk profile without increased event prevalence in late-onset Pompe disease: an individually matched cohort study.Orphanet journal of rare diseases
EsetismertetésSensory neuronopathy secondary to gene therapy with AT845 for Pompe disease.Neuromuscular disorders : NMD
EsetismertetésCombined omalizumab and desensitization to control IgE-mediated hypersensitivity in enzyme replacement therapy for late-onset Pompe disease.Orphanet journal of rare diseases
[Clinical and genetic characteristics of infantile-onset Pompe disease and long-term efficacy of enzyme replacement therapy].Zhonghua er ke za zhi = Chinese journal of pediatrics
Clinical, pathological and genetic features as well as follow-up of 68 patients with late-onset Pompe disease: a single-center retrospective study.Frontiers in nutrition
The Value of Anti-Drug Antibody Detection in Discriminating Patients from Healthy Controls and Predicting the Gross Motor Functional State in Patients with Pompe Disease.Iranian journal of allergy, asthma, and immunology
Detection of Altered Muscle Glycogen- and NOE-Weighted CEST MRI Signals in an Acid Alpha-Glucosidase-Deficient Mouse Model of Pompe Disease Using QUASS-Enhanced Multi-Pool Quantitative CEST (QCEST) Imaging.Magnetic resonance in medicine
ÁttekintésPompe Disease: Pathogenesis, Molecular Mechanisms, Neurological Aspects, Diagnostics and Modern Therapeutic Approaches.International journal of molecular sciences
Szisztematikus áttekintésCardiac magnetic resonance in Pompe disease: a systematic literature review.La Radiologia medica
Cost-Effectiveness of Newborn Screening for Infantile-Onset Pompe Disease in Japan.International journal of neonatal screening
Dietary and body composition profiles in Chinese pediatric late-onset Pompe disease: implications for nutritional management.Frontiers in medicine
Antibody formation and efficacy of enzyme replacement therapy in adults with Pompe disease: Unlocking long-term insights.Genetics in medicine : official journal of the American College of Medical Genetics
Over ten years of newborn screening for LSDs in Tuscany (Italy): Epidemiology, novel variants, and the pseudodeficiency burden.Molecular genetics and metabolism
ÁttekintésEpigenetic modulation of the gut-muscle axis in pompe disease: Microbiota fingerprints to cellular and molecular pathomechanisms.Molecular metabolism
Restoration of lysosomal membrane integrity in cell models of Pompe disease depends on fatty acid synthase and its product palmitic acid.Cellular & molecular biology letters
Multidimensional assessment of diaphragmatic dysfunction in late-onset Pompe disease: a prospective cohort study.Orphanet journal of rare diseases
Early enzyme replacement therapy in late-onset Pompe disease diagnosed by newborn screening.Molecular genetics and metabolism
A genome-edited isogenic human embryonic stem cell model of pompe disease recapitulates cardiac and skeletal muscle pathology.Molecular biology reports
Increased Glycogenin-Exposed Residual Glycogen in Lysosomes Is the Early Pathological Finding in Asymptomatic Pompe Disease.Muscle & nerve
EsetismertetésManagement of life-threatening anaphylaxis to enzyme replacement therapy in an infant with Pompe disease: a case report and literature review.Frontiers in allergy
ÁttekintésGenetic Mutations Underlying Growth Impairment and Cardiomyopathies in Children: Molecular Mechanisms, Clinical Implications and Targeted Therapies.Genes
Patient Perspectives on Late-Onset Pompe Disease: Insights From a 2025 Patient Snapshot Survey on Diagnosis, Treatment, and Quality of Life.Journal of patient experience
EsetismertetésIntegration of deep intronic and RNA sequencing enhances molecular diagnosis in genetically unsolved Pompe cases.Molecular genetics and metabolism reports
Mapping lung function in late-onset Pompe disease using label-free functional MRI.iScience
Alglucosidase alfa demonstrates effectiveness and safety in Chinese patients with late-onset Pompe disease: A multi-center prospective study.Molecular genetics and metabolism
Identification of alterations of immunometabolism associated with Pompe disease.Cellular and molecular life sciences : CMLS
Impacts and Economic Burden of Pompe Disease on Patients and Families in Thailand: A Mixed Method Study.ClinicoEconomics and outcomes research : CEOR
Gait analysis reveals new outcome measures for monitoring disease progression in individuals with late-onset Pompe disease.Journal of neuroengineering and rehabilitation
EsetismertetésEarly-onset Pompe disease: an imaging spectrum.QJM : monthly journal of the Association of Physicians
ÁttekintésComprehensive review of recent advances in Pompe disease: pathogenesis, management, and future directions.Frontiers in neurology
Longitudinal Motor Function Changes in Adults With Late-Onset Pompe Disease: Key Determinants and Clinical Thresholds.Neurology
Design of multivalent pharmacological chaperones against Pompe disease via metal-free ligation.Organic & biomolecular chemistry
ÁttekintésMiglustat: a first-in-class enzyme stabilizer for cipaglucosidase alfa for the treatment of late-onset Pompe disease.Therapeutic advances in rare disease
MetaanalízisComparing the efficacy of cipaglucosidase alfa plus miglustat with alglucosidase alfa for late-onset Pompe disease: an expanded network meta-analysis utilizing patient-level and aggregate data.Journal of comparative effectiveness research
Generation and characterization of a novel Gaa compound heterozygous mouse model recapitulating human Pompe disease.Orphanet journal of rare diseases
Szisztematikus áttekintésLessons from late-onset Pompe disease identified by Newborn screening: A systematic review.Molecular genetics and metabolism
Mapping glycogen accumulation and treatment effect in Pompe disease with saturation transfer MRI.Translational research : the journal of laboratory and clinical medicine
EsetismertetésShort-Term Intensive Avalglucosidase Alfa Regimen in Late-Diagnosed Infantile Pompe Disease: A Case Report.Reports (MDPI)
Pompe disease: a country-wide molecular screening in a cohort of 15,068 study participants.Frontiers in molecular biosciences
Szisztematikus áttekintésEnzyme replacement therapy compared with best supportive care for the treatment of Pompe Disease: a systematic review and network meta-analysis.Health technology assessment (Winchester, England)
ÁttekintésA roadmap for a patient-centred approach to Pompe disease management.Journal of neurology
Megfigyeléses vizsgálatFirst multicenter real-world analysis of switching to next-generation enzyme replacement therapies in late-onset Pompe disease.Journal of neurology
Gastrointestinal manifestations and enzyme replacement therapy in late-onset Pompe disease: insights from a cross-sectional analysis.Orphanet journal of rare diseases
ÁttekintésMeasuring What Matters to Patients with Pompe Disease: A Review of Clinical Outcome Assessments for Capturing Treatment Benefits of Innovative Novel Therapies.Advances in therapy
Randomizált vizsgálatClinically important improvements in 6-minute walk distance and forced vital capacity in adults with late-onset Pompe disease switching from alglucosidase alfa to cipaglucosidase alfa plus miglustat in the PROPEL study.Neuromuscular disorders : NMD
Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease.Neuromuscular disorders : NMD
Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials.Therapeutic advances in rare disease
Longitudinal characterization of Gaac.1826dupA mice reveals the cardiac, myopathic and biochemical phenotypes of Pompe disease.Disease models & mechanisms
Early Initiation of Enzyme Replacement Therapy in Infantile Onset Pompe Disease Improves Cardiac Outcomes: A Longitudinal Analysis.JIMD reports
Szisztematikus áttekintésInsights into immunogenicity and therapeutic strategies to mitigate the immune response in infantile-onset Pompe disease: a comprehensive systematic literature review.Frontiers in immunology
ÁttekintésA comprehensive study on the effect of alglucosidase alpha and immunomodulation on survival, motor and cardiac outcome, creatine kinase and antibody titers in classic infantile Pompe disease: the Monza experience.Current opinion in immunology
GMPPB-CDG Results in Lysosomal Dysfunction and Acid Alpha-Glucosidase Deficiency.Journal of inherited metabolic disease
Quantitative MRI Biomarkers for Early Muscle Involvement in Late Onset Pompe Disease.Journal of inherited metabolic disease
EsetismertetésSuccessful desensitization to alglucosidase alfa in a very young infant with Pompe disease.Journal of pediatric endocrinology & metabolism : JPEM
Identification of miRNAs Associated with Infantile-Onset Pompe Disease.Molecular syndromology
Austrian Pompe Outcome Consensus (APOC): a national Delphi study.Orphanet journal of rare diseases
Early initiation of enzyme replacement therapy as facilitated by newborn screening improves health outcomes among patients with infantile-onset Pompe disease.Genetics in medicine open
EsetismertetésRapid Regression of Myocardial Hypertrophy with First-Line Avalglucosidase Alfa in Infantile-Onset Pompe Disease: A Case Report.Pediatric cardiology
Novel promoters drive therapeutic transgene expression and evade transgene-specific immune responses in a mouse model of Pompe disease.Molecular genetics and metabolism
Plasma glial fibrillary acidic protein (GFAP) is a biomarker for central nervous system involvement in infantile-onset Pompe disease.EBioMedicine
EsetismertetésIntegrating enzyme assay and molecular genetic testing for early diagnosis of infantile-onset Pompe disease: A case report.Molecular genetics and metabolism reports
Response to: Correspondence on 'Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements' by Barzel et al.European journal of hospital pharmacy : science and practice
EsetismertetésEnzyme replacement therapy during pregnancy and breastfeeding in late-onset Pompe disease.International breastfeeding journal
Evaluation of Experienced Clinical Events in Pompe Disease Based on Real-life Data.Neuropediatrics
ÁttekintésDiagnosis, management and monitoring of patients with Pompe disease in the UK.BMJ neurology open
IrányelvRecommendations for the diagnosis, treatment, and follow-up of late-onset Pompe disease.Neurologia
ÁttekintésNew advances in treating late-onset Pompe Disease: A narrative review.European journal of pediatrics
Correspondence on "Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements" by Barzel et al.European journal of hospital pharmacy : science and practice
Neutral sp2-iminosugars exploiting non-glycone interactions for selective acid α- and β-glucosidase activity modulation: Pharmacological chaperones for Gaucher and Pompe diseases.European journal of medicinal chemistry
Correction: Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Focused ultrasound delivery of enzyme replacement therapy to the brain of Gaa-/- Pompe disease mice.Molecular genetics and metabolism
A respiratory signature of disease progression in the Pompe rat.Journal of neurophysiology
ÁttekintésEnzyme Replacement Therapy & Other Therapeutic Frontiers in Infantile Metabolic Disorders.NeoReviews
Late-onset Pompe's disease in pediatrics: results from an Italian national survey on 38 patients and proposal of a targeted diagnostic algorithm.Orphanet journal of rare diseases
Elevated Transaminases: Does It Always Warrant a Liver Biopsy? Lessons Learned From Pompe Disease.JIMD reports
Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Megfigyeléses vizsgálatLong-term safety outcomes and patient preferences for home-based intravenous enzyme replacement therapy (ERT) in Pompe disease and Mucopolysaccharidosis Type I (MPS-I): final results of two-year observation.Orphanet journal of rare diseases
EsetismertetésCipaglucosidase alfa plus miglustat in Pompe disease: two non-ambulatory patients switching from high‑dose, high-frequency alglucosidase alfa.Neuromuscular disorders : NMD
The cost-effectiveness of enzyme replacement therapies versus best supportive care for treating late onset Pompe disease in the UK NHS.The European journal of health economics : HEPAC : health economics in prevention and care
EsetismertetésPresymptomatic late-onset Pompe disease: Optimizing the timing of treatment.Revue neurologique
When the Diaphragm Fails: Visual Hallucinations Due to Isolated Respiratory Muscle Weakness as a First Manifestation of Late-Onset Pompe Disease.European journal of case reports in internal medicine
Hypertrophic cardiomyopathy in Pompe disease following avalglucosidase alfa therapy.Anales de pediatria
ÁttekintésRe-anchoring the Value of Innovative Therapies in NICE Decision Making When Comparators are Cost Ineffective: A Case Study of Late-Onset Pompe Disease.PharmacoEconomics
Megfigyeléses vizsgálatMedical expenses and care pathways of patients with Pompe receiving myozyme: an observational study based on the French national healthcare database.Orphanet journal of rare diseases
EsetismertetésAnaesthetic Management of Advanced Late-Onset Pompe Disease: Challenges in a Major Abdominal Surgery.Cureus
A retrospective cohort study describing the disease burden in patients with Pompe disease treated with enzyme replacement therapy in the United States.Journal of neuromuscular diseases
Causes of Death and Comorbidities in Adult Patients With Late-Onset Pompe Disease: A French Pompe Registry Retrospective Study.European journal of neurology
Editorial Note: The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease.PloS one
EsetismertetésDermatomyositis masking late onset Pompe disease in a patient with proximal muscle weakness.Journal of neuromuscular diseases
EsetismertetésIn Thickness and in Health: Delayed-Onset Pompe Disease Resembling Hypertrophic Cardiomyopathy.Cureus
Megfigyeléses vizsgálatQuantification of muscle glycogen distribution in Pompe disease using 7 Tesla 13C NMR spectroscopy.Journal of neurology, neurosurgery, and psychiatry
Reduction of false-positive results with biochemical second-tier testing for newborn screening of Pompe disease.Genetics in medicine : official journal of the American College of Medical Genetics
Molecular characterization of a novel synonymous variant in a Mexican patient with Pompe disease.Molecular genetics and metabolism reports
Áttekintés[Neuromuscular diseases in pediatrics with specific treatments].Medicina
Quantitative muscle ultrasound as a window into disease progression in infantile-onset Pompe disease.Molecular genetics and metabolism
Infantile-onset Pompe disease entering adulthood: Insights from 2 decades of enzyme replacement therapy experience.Genetics in medicine : official journal of the American College of Medical Genetics
Umbilical Cord Blood Sampling for Newborn Screening of Pompe Disease and the Detection of a Novel Pathogenic Variant and Pseudodeficiency Variants in an Asian Population.International journal of neonatal screening
Correction of Disease Phenotype in Pompe Disease Knockout Mice Following Cationic Lipid-GL-67-Mediated Gene Therapy.DNA and cell biology reports
C-Branched Iminosugars as Selective Pharmacological Chaperones of Lysosomal α-Glucosidase for the Treatment of Pompe Disease.Journal of medicinal chemistry
Genotype-phenotype correlation and CRIM status in Vietnamese children with Pompe disease: a single-center experience.Future science OA
ÁttekintésPompe Disease: A Review of Diagnosis, Molecular Genetics, and Treatment Management.Current cardiology reviews
Management of hypersensitivity in a patient with late-onset Pompe disease experiencing recurrent infusion-related reactions.Journal of neurology
Therapeutic acute intermittent hypoxia modestly improves breathing in Pompe disease.Respiratory physiology & neurobiology
A myotropic AAV vector combined with skeletal muscle cis-regulatory elements improve glycogen clearance in mouse models of Pompe disease.Molecular therapy. Methods & clinical development
An Indirect Treatment Comparison of Avalglucosidase Alfa versus Cipaglucosidase Alfa Plus Miglustat in Patients with Late-Onset Pompe Disease.Advances in therapy
EsetismertetésMarked Improvements in Airway Abnormalities and Multifaceted Outcomes After 2 Years Switching to Avalglucosidase Alfa: Evaluation of A 19-Year-Old Male Diagnosed With Late-Onset Pompe Disease.American journal of medical genetics. Part A
ÁttekintésNavigating the Emotional and Practical Challenges of Newborn Screening for Late-Onset Pompe Disease: Insights From Parental Perspectives.Pediatric neurology
Efficacy of avalglucosidase alfa in infantile-onset Pompe disease with high anti-alglucosidase alfa antibody titers.Pediatrics international : official journal of the Japan Pediatric Society
A retrospective cohort study of the economic burden of Pompe disease in patients treated with enzyme replacement therapy in the United States.Journal of medical economics
Generation and characterization of three human induced pluripotent stem cell lines from patients with glycogen storage disease type II.Stem cell research
Cipaglucosidase alfa and miglustat for treatment of late-onset Pompe disease (LOPD): A therapeutics bulletin of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine open
Novel transferrin receptor-mediated enzyme replacement therapy efficiently treats myogenic and neurogenic aspects of Pompe disease in mice.Molecular therapy. Methods & clinical development
Molecular Screening of Feline Glycogen Storage Disease Type II (Pompe Disease): Allele Frequencies of the GAA:c.1799G>A and c.55G>A Variants.Genes
Identification of a Pathogenic Mutation for Glycogen Storage Disease Type II (Pompe Disease) in Japanese Quails (Coturnix japonica).Genes
MetaanalízisEnzyme replacement therapy for the treatment of late onset Pompe disease: A systematic review and network meta-analysis.Orphanet journal of rare diseases
Determination of the Epitopes of Alpha-Glucosidase Anti-Drug Antibodies in Pompe Disease Patient Plasma Samples.Antibodies (Basel, Switzerland)
EsetismertetésAn uncommon case of neonatal asphyxia associated with infantile-onset Pompe disease.Italian journal of pediatrics
Stability of alglucosidase alfa in 0.9% sodium chloride for enzyme replacement therapy in patients with Pompe disease: insights from enzyme activity and cellular uptake measurements.European journal of hospital pharmacy : science and practice
Randomizált vizsgálatEfficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial.Journal of neurology
Extensive digital health technology assessment detects subtle motor impairment in mild and asymptomatic Pompe disease.Scientific reports
Efficacy of Switching Therapy From Alglucosidase Alfa to Avalglucosidase Alfa on Respiratory Function in Participants With Late-Onset Pompe Disease: A Post Hoc Analysis From the COMET Trial.JIMD reports
ÁttekintésLatest Advancements in Treatment Options for Infantile-Onset Pompe Disease: A Comprehensive Narrative Review.Clinical medicine insights. Pediatrics
EsetismertetésAtrioventricular Block in a Pompe Disease Patient Receiving Enzyme Replacement Therapy.JACC. Case reports
Correction: Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.Journal of neurology
Autophagy impairment is associated with enhanced satellite cell activation in muscle biopsies from younger late-onset Pompe disease patients.Journal of neuropathology and experimental neurology
Szisztematikus áttekintésExpert opinion on clinical presentation, diagnosis, and treatment of infantile-onset Pompe disease: a Delphi study in Türkiye.Turkish journal of medical sciences
Long-Term Functional Correction of Pompe Disease and Increased α-Glucosidase Expression after Gene Therapy with Novel Combinations of Muscle-Targeted Transcriptional Cis-Regulatory Elements.Human gene therapy
EsetismertetésResults of orthodontic procedure in a patient with classic infantile Pompe disease.Italian journal of pediatrics
Megfigyeléses vizsgálatAnalysis of the Italian cohort of late-onset Pompe disease (LOPD) patients after 10 and 15 years of therapy with alglucosidase alfa.Journal of neurology
EsetismertetésCase Report: Incidental late-onset Pompe disease diagnosis in a man with no clinical and instrumental evidence of neuromuscular dysfunction.Frontiers in genetics
Pompe Disease: Current State and Future Treatments.Cardiology in review
Gene Therapy for Infantile-Onset Pompe's Disease.The New England journal of medicine
Vizsgálati eredményAAV9-Mediated Gene Therapy for Infantile-Onset Pompe's Disease.The New England journal of medicine
Clinical and therapeutic clues from a long-term follow-up: a single center experience on a large LOPD population.Journal of neurology
Neonatal systemic gene therapy restores cardiorespiratory function in a rat model of Pompe disease.Molecular therapy : the journal of the American Society of Gene Therapy
An Assessment of Dietary Intake, Feeding Practices, Growth, and Swallowing Function in Young Children with Late-Onset Pompe Disease: A Framework for Developing Nutrition Guidelines.Nutrients
Successful Pregnancy Outcome in Patient with Pompe Disease Despite Discontinuation of Enzyme Replacement Therapy.European journal of case reports in internal medicine
Unexplained Progressive Respiratory Insufficiency and Weakness Diagnosed as Late-Onset Pompe Disease Through Biochemical and Molecular Genetic Testing.The Neurohospitalist
ÁttekintésEnzyme replacement therapies in adults with Pompe disease: from trials to real-world data.Current opinion in neurology
Vizsgálati eredményThe Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.The Journal of pediatrics
Szisztematikus áttekintésThe involvement of central nervous system across the phenotypic spectrum of Pompe disease: a systematic review.Neuromuscular disorders : NMD
Randomizált vizsgálatDefining clinically meaningful thresholds for forced vital capacity in patients with neuromuscular disorders: Lessons learned from the COMET study in Pompe disease.Journal of neuromuscular diseases
Characterization and Related Factors of Postural Control in Adults With Late-Onset Pompe Disease: Cross-Sectional and Case Control Study.Physical therapy
Screening for Pompe disease in Serbian patients with limb-girdle muscle weakness.Clinical neurology and neurosurgery
Randomizált vizsgálatSwitching Enzyme Replacement Therapy for Late-Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL.Muscle & nerve